

January 10, 1966

Dr. J. Robert Hewson  
Assistant Director  
Clinical Investigation  
McNeil Laboratories, Inc.  
Camp Hill Road  
Fort Washington, Pennsylvania 19034

Dear Dr. Hewson:

In response to your letter of January 6, I have asked the nursing supervisor to obtain the information regarding the cholesterol levels in our patients receiving trifluoperidol. As soon as that is available I will send it on to you.

I have had a number of questions raised about the draft of the trifluoperidol report which I sent to you. One of the questions was a better justification concerning the biphasic effects on motor function related to dosage which we noted in our study program. As I reviewed our data I became more impressed that this compound may very well have anticholinergic properties at higher dosages. While I have been stimulated to elaborate this view in the discussion, I would be interested in any additional comments you might be willing to make at this time regarding the potential anticholinergic properties of this compound in higher dosage.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp